Tau protein is implicated in many neurogenerative diseases, including Alzheimer s. New findings point to a new potential drug target to slow the progress of the disease: the enzymes responsible for sulfation called heparan sulfate 3-O transferases.
New Alzheimer s Drug Target Discovered miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Fishing for new source of proteoglycans, an important health food ingredient miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Scientists from Japan and the United States have identified a new mechanism of blood-brain barrier degradation in the post-stroke brain, involving acrolein-induced modifications of proheparanase. This discovery could lead to the production of newer and more effective drugs for stroke-related disorders. Credit: Toubibe from Pixabay Read Time:
The blood-brain barrier prevents immune cells from circulating freely in the brain, and the breakdown of its function is a major cause of post-stroke inflammation. Now, for the first time, researchers have identified how a toxic stroke byproduct, acrolein, could activate the barrier-degrading enzyme proheparanase (proHPSE). The research group has discovered that proHPSE degrades the glycocalyx within the post-stroke brain s blood vessels, providing hope for new and effective therapeutics against post-stroke inflammation.